dioxy)-5-methyl-7-hydroxy-8-methoxy-benzo[c]phenanthridinium, called NK109, synthesized by Suzuki and colleagues, has been shown by Kabasawa et al (1996) to act strongly against several murine cell lines including P388, L1210 leukaemia, colon 26 and B 16 melanoma as well as against a panel of human tumour cell lines. Its chemical structure is shown in Figure 1 . The efficacy of NKl09 against human tumour xenografts, including lung, stomach, colon and ovarian carcinomas, demonstrates superiority to etoposide and similarity to doxorubicin or cisplatin. In cell-free systems, NK109 inhibits topo II activity through the stabilization of the cleavable complex. NK109 increases the amount of cellular DNA-protein complex and induces DNA strand breaks more intensely than either the other benzophenanthridine alkaloids or the topo II inhibitor, etoposide (Kabasawa et al, 1996) . In this study, NK109 was found to be active against cisplatin-, doxorubicin-and etoposide-resistant tumour cells. From these results, we believe that NK109 will be useful for the treatment of refractory solid tumours.
MATERIALS AND METHODS
Anti-tumour drugs and materials 2,3-(Methylenedioxy)-5-methyl-7-hydroxy-8-methoxy-benzo- [c] phenanthridinium hydrogensulphate dihydrate (NK109) and its tritium-labelled form were obtained from Nippon Kayaku (Tokyo, Japan) . Cisplatin and etoposide were provided by Bristol Myers Japan (Tokyo, Japan), and doxorubicin was purchased from Kyowa Hakko Kogyo (Tokyo, Japan). Supercoiled Escherichia coli plasmid pBR322 DNA and kinetoplast DNA (kDNA) were purchased from Takara Shuzo (Kyoto, Japan) and purified DNA Topo II was obtained from TopoGEN (Columbus, OH, USA). Tritium-labelled azidopine was purchased from Moravek Biochemicals (Brea, CA, USA). RPMI-1640 medium (Gibco-BRL) and fetal bovine serum (FBS) were purchased from Nissui (Tokyo, Japan).
Cell lines and culture
The cell lines used were the human cancer cell lines, H69, SBC-3 (small-cell lung cancer), PC-9, PC-14 (non-small-cell lung cancer), MCF7 (breast cancer), SKOV3 (ovarian carcinoma), K562 (leukaemia cells) and their drug-resistant sublines. H69 and SBC-3 were obtained from the National Cancer Institute, Bethesda, MD, USA, and the Japanese Cancer Research Resources Bank (Tokyo, Japan) respectively. PC-9 and PC-14 were from Professor Y Hayata (Tokyo Medical College, Tokyo, Japan). MCF7 and SKOV3 were kindly donated by Dr KH Cowan (National Cancer Institute, Bethesda, MD, USA) and Dr S Niimi (Jikei University, Tokyo, Japan) respectively.
The etoposide-resistant cell lines H69/VP ) and SKOV3/VP (Kubota et al, 1994) and the cisplatin-resistant PC-9/CDDP and PC-14/CDDP (Hong et al, 1988) were established in our laboratory by continuous exposure of cells to stepwise increasing concentrations of drugs, followed by isolation and growth of resistant clones. The doxorubicin-resistant cell lines K562/ADM (Tsuruo et al, 1986) , AdrR MCF7 (Cowan et al, 1986) and SBC-3/ADM (Kimura et al, 1987) were donated by Dr T Tsuruo (Tokyo University, Tokyo, Japan), Dr KH Cowan (National Cancer Institute) and Dr T Ohnoshi (Okayama University, Okayama, Japan) respectively. AdrR MCF7, SBC-3/ADM and H69/VP over-express P-glycoprotein (P-gp) and are considered to have typical P-gp-mediated multidrug resistance (MDR) phenotypes. SKOV3NP is considered to be an 'atypical MDR' cell line.
The cells were routinely maintained in RPMI-1640 medium supplemented with 10% heat-inactivated FBS, streptomycin (100 gg ml-') and penicillin (100 IU ml-') in an incubator under a humidified atmosphere of 5% carbon dioxide and 95% air at 370C, as described previously . The cells were subcultured every week in the exponential growth phase. The stability of the drug-resistant phenotypes was confirmed by assessing the growth curves of cells in the presence of the drug concerned.
In vitro cytotoxic effect assay test
The cytotoxic effect was estimated using the regrowth assay described previously (Kanzawa et al, 1995) . Duplicate 10-ml culture flasks, initially containing 2.5 x 104 cells per ml of medium and the required drugs at various concentrations, were incubated for 7 days at 37°C in the incubator, after which the cells were counted using a TOA Microcellcounter CC-108 (TOA Medical Electronics, Kobe, Japan) and the cell proliferation ratios of treated vs control cultures were calculated. Drug antiproliferative activities were expressed as IC50 values, which are the concentrations required to inhibit cell proliferation by 50% compared with control cultures.
Preparation of nuclear extracts
Crude nuclear extracts were prepared as reported previously by Deffie et al (1989) . Cells were collected by centrifugation and washed twice with ice-cold 2 mM dipotassium hydrogen phosphate, 5 mm magnesium chloride, 150 mm sodium chloride, 1 mM EGTA, 0.1 mM dithiothreitol, pH 6.5 (nucleus buffer, NB). The cells were resuspended in 1 ml of cold NB, and 9 ml of cold NB containing 0.35% Triton X-100 and 1 mM polymethyl sulphonyl fluoride was added. The cell suspension was put on ice for 10 min and washed with Triton X-100 free cold NB. Nuclear protein was eluted for 1 h at 4°C with cold NB containing 0.35 M sodium chloride. A solution of nuclear protein was obtained by centrifugation at 18 000 g for 10 min. Protein concentration was determined by the method of Bradford with bovine plasma y-globulin as the standard.
DNA topo I and 11 catalytic activity Topo I activity was determined by measuring the relaxation of supercoiled pBR322 DNA, as described by Liu and Miller (1981) . The reaction mixtures comprised 100 mM potassium chloride, 1O mm magnesium chloride, 1 mm dithiothreitol, 0.1 mM EDTA, 10% glycerol, 50mM Tris-HCl (pH 7.4) and 0.7 jg of pBR322 DNA. The reaction was initiated by the addition of crude nuclear extracts (0.0003-1.0 jig ml-') and allowed to proceed at 370C for 20 min. Reactions were terminated by adding 5 gl of dye solution containing 1% sodium dodecylsulphate (SDS), 0.05% bromophenol blue and 10% sucrose. These samples were applied to 0.7% agarose gels, electrophoresed for 4.5 h with a Tris-acetate running buffer with EDTA, after which the gel was stained with 2 jM ethidium bromide and photographed under transillumination with 300 nm UV light.
Topo II catalytic activity was assayed by two different methods: (1) relaxation of supercoiled pBR322 DNA to relaxed forms and (2) decatenation of kDNA into free mini-circles. The former was performed to examine the inhibiting effect of NK109 on the Topo II catalytic activity. The reaction mixtures comprised 100 mm potassium chloride, 10 mm magnesium chloride, 5 mM dithiothreitol, 0.5 mM EDTA, 10% glycerol, 50 mm Tris-HCl (pH 7.4), bovine serum albumin 10 jg ml' and 1 mim adenosine 5'-triphosphate (pH 7.7). The reactions were started by addition of purified DNA Topo II in the presence of supercoiled pBR322 DNA (1.0 jg) and NK109 (0.05-100 jg ml-'), allowed to proceed at 30°C for 15 min and the reactions were terminated by adding 5 jl of dye solution. These samples were applied to 1.0% agarose gels, electrophoresed for 3 h with a Tris-acetate running buffer with EDTA, after which the gels were stained and photographed (Marini, 1980) . Decatination of kDNA was used to determine the Topo II catalytic activity of crude nuclear extracts of tumour cells using kDNA as a substrate. Reaction conditions were as described above except that 1.0 jg of kDNA was used as substrate instead of pBR322 DNA. The reaction was initiated by the addition of crude British Journal of Cancer (1997) nuclear extracts (0.001-1.0,g ml-') and incubated at 30°C for 15 min. The subsequent process was carried out as described above.
Cleavage of DNA by Topo 11 All DNA cleavage reactions used Topo 11 (10 jig ml-') and negatively supercoiled pBR322 DNA (50 jig ml-') in a total volume of 20 gl of cleavage buffer (10 mm Tris-HCl, pH 7.9, 50 mm sodium chloride, 50 mm potassium chloride, 0.1 mM EDTA and 2.5% glycerol) that contained 5 mm magnesium chloride. Samples were incubated for 6 min at 30°C. Cleavage products were trapped (Liu et al, 1983 ) by the addition of 2 gl of 10% SDS. An aliquot (1 ,ul) of 250 mm EDTA and 2 ,ul of a 0.8 mg ml-' solution of proteinase K was added, and samples were incubated at 37°C for 30 min to digest the Topo II. Final products were mixed with 2.5,l of loading buffer (60% sucrose, 0.05% bromophenol blue, 0.05% xylene cyanole FF, and 10 mM Tris-HCI, pH 7.9), heated at 70°C for 1 min, and subjected to electrophoresis in 1% agarose (MCB) gels in 40 mm Tris-acetate and 2 mm EDTA at 4 V cm-'. After electrophoresis; DNA bands were stained with ethidium bromide Reaction mixtures (20 gl each) containing purified DNA Topo II and pBR322 DNA and NK1 09 or etoposide at concentrations of 25 and 50 or 12.5 and 25 9g ml-1, respectively, were incubated at 370C for 10 min, and then were terminated by addition of 4 ,ul of 5% SDS and proteinase K at 2 mg ml-' (SDS/PK). Proteinase K digestion was performed at 370C for 30 min.
Reaction mixtures were then analysed by 1.0% agarose gel electrophoresis. The resulting bands were identified as relaxed, linear and supercoiled forms of various topological isomers of pBR322 DNA and visualized by transillumination with ultraviolet light (300 nm). The bands were photographed through Kodak 24A and 12 filters using Polaroid type 665 positive-negative film.
Drug accumulation study
The accumulation of [3H]NK109 in the cells was determined by a previously described method (Kanzawa et al, , 1995 . For evaluation of drug accumulation, exponentially growing cells were harvested, 2 x 107 cells in 0.98 ml of culture medium were preincubated at 37°C in a water bath for 45 min and the cells were then exposed to 75 gM [3H]NK109 at 37'C in a humidified incubator with 5% carbon dioxide. After various incubation times, the cells were collected by low-speed centrifugation, washed once with icecold PBS and centrifuged. The resulting cell pellet was dissolved in 0.5 ml of 90% formic acid. Clear-sol TM 1 solution (3 ml; Nacalai Tesque, Kyoto, Japan) was added to each tube and the radioactivity was measured using a liquid scintillation counter (LS6000TA, Beckman Instruments, Irvine, CA, USA). For the efflux study, cells were incubated with RPMI-FBS containing 75 jiM [3H]NK109 at 37°C for 60 min before being washed twice with drug-free medium.
The subsequent process was then carried out as described above.
Detection of P-glycoprotein expression by flow cytometry
For flow cytometric analysis 
RESULTS

Catalytic activity of DNA Topo 11
First, we confirmed the inhibiting effect of NK109 on DNA Topo II catalytic activity that was reported to be the mechanism of cytotoxicity of NK109 (Kabasawa et al, 1996) . Catalytic activity of Topo II was assayed by relaxation of supercoiled pBR322 DNA and the result is shown in Figure 2 . In the absence of Topo II, pBR322 DNA migrates predominantly in the fast moving supercoiled state. Addition of Topo II without drug results in conversion of the supercoiled form into the relaxed DNA configurations. NK109 inhibited the ability of Topo II to relax supercoiled DNA at 5 jig ml-' However, at concentrations of less than 20 jg ml-', NK109 did not inhibit the relaxation. As a reference compound, etoposide also inhibited the relaxation of pBR322 DNA by Topo II at the same concentration as shown in Figure 2 . NK109 inhibits the catalytic activities of purified DNA Topo II in vitro, and its efficacy is as high as etoposide.
Effect of NK109 on the DNA cleavage of topo 11
The effect of NK109 on the DNA cleavage of Topo II was studied by 25-50 jg ml-' drug in reaction mixtures (Figure 3) . Topo IImediated DNA strand passage requires breaking and rejoining of the double-stranded DNA. During this process, the enzyme becomes covalently linked to the 5'-phosphate of both DNA strands via a tyrosine-DNA phosphodiester of both DNA strands via a tyrosine-DNA phosphodiester linkage (Tse et al, 1980) . The covalent reaction intermediate is called the cleavable complex and can be demonstrated experimentally by the enzyme-dependent formation of linear DNA from supercoiled DNA after treatment with SDS and proteinase K (Liu et al, 1983) . Clinically used DNA topoisomerase II inhibitors such as doxorubicin and etoposide act by stabilizing the cleavable complex Ross et al, 1984; Tewey et al, 1984) . NK109 at concentrations up to 10 jig ml-' did not induce DNA cleavage (data not shown). In contrast, 25 jg ml-l NK109 completely inhibited the cleavable complex formation as shown in Figure 3 . A similar effect was also observed in the treatment using etoposide. These results suggest that DNA Topo II is a target of NK109 action and this action may play a role in the cytotoxicity of NK109.
In vitro growth-inhibiting activity of NK109 in drugresistant cells
We examined whether NK109 showed cytotoxicity against a panel of multidrug-resistant cell lines, such as K562/ADM, AdrR MCF7, SBC-3/ADM and H69/VP. The sensitivity or resistance was verified by regrowth assays in a continuous drug exposure system. Resistance indices were determined by comparing the toxic doses allowing 50% survival (IC 50) of resistant cell lines with their parent cell lines. Resistance indices of K562/ADM, AdrR MCF7 and SBC-3/ADM were 59.8-, 62.0-and 10.2-fold as shown in Figure 4A -C respectively. The cytotoxicity of NK109 against these three doxorubicin-resistant cell lines was determined. The IC 5, of NK109 for K562/ADM cells was 0.045 jg ml-', which is almost the same as that (0.041 jg ml-') of the parent cell line, suggesting no cross-resistance to NK109, as shown in Figure 4A .
The IC 5, of NK109 for AdrR MCF7 cells was 0.42 jg ml-' which is 2.1 times that (0.20 jg ml-') of the parent cell line ( Figure 4B ). SBC-3/ADM cells were almost as sensitive to NK109 as SBC-3/P cells ( Figure 4C ). The etoposide-resistant H69/VP cell line, having a typical P-gp-mediated MDR phenotype, also showed no crossresistance to NK109 ( Figure 4G ).
Cisplatin-resistant PC-9/CDDP and PC-14/CDDP human nonsmall-cell lung cancer cells were examined for cross-resistance to NK109. The resistance ratios of PC-9/CDDP cells and PC-14/CDDP cells for cisplatin were 4.4-and 12.9-fold respectively. The cytotoxicities of NK109 against these cisplatin-resistant cell lines were estimated. The IC50 of NK109 for PC-9/CDDP cells was 0.19 jig ml-', which is almost the same as for the parental cell line (0.17 jig ml-') ( Figure 4D ). PC-14/CDDP cells showed no cross-resistance to NK109 as shown in Figure 4E . Thus, NK109 was effective against cisplatin-resistant PC-9 and PC-14 cells as well as against their parental cells.
We postulated that NK109 would not inhibit the growth of etoposide-resistant cells because NK109 is thought to exert its cytotoxicity by the formation of cleavable Topo II complexes, as does etoposide. SKOV3/VP cells are 9.6-fold resistant to etoposide and decreased Topo II activity is the resistance mechanism (Kubota et al, 1994) . the IC 5, of NK109 for the growth of SKOV3/VP cells was 0.21 jig ml-', which is little higher than that of the parental cells ( Figure 4F ). Thus, contrary to expectation, we did not observe cross-resistance of SKOV3/VP cells to NK109.
Intracellular accumulation of NK109 in drug-resistant cells
We studied reactions of NK109 with several molecular and biological alterations associated with resistance. First, the time course of NK109 uptake by K562 cells was determined, because resistance to anti-tumour drugs is frequently characterized by diminished British Journal of Cancer (1997) 76(5) VH]NK109 (0.5 pCi), the cellular uptake of NK109 into K562/ADM cells was the same as that in the parental cells. Further, we determined the efflux of NK109 from the resistant cells compared with the parent cells and the results are shown (0 and * for K562/P and K562/ADM respectively) in Figure 5 . Efflux did not differ between the cell lines, as shown in Figure 5 . The mechanism of resistance of the cisplatin-resistant PC-14/CDDP cell line is thought to be impaired drug uptake, so we determined the cellular uptake of NK109 by PC14/P and PC 1 4/CDDP cells. No difference in the uptake of NK 109 between these cell lines was observed (data not shown).
Detection of P-gp in doxorubicin-resistant cells
The K562/ADM and AdrR MCF7 cells were confirmed to be P-gp positive. Flow cytometric overlay histograms of isotype controls and MRK-16 antibody-treated cells are shown in Figure 6 . In the parental cell lines K562 and MCF7, less than 1% of cells stained positive with the P-gp-specific MRK-16 monoclonal antibody (data not shown). In contrast, both K562/ADM and AdrR MCF7 cells reacted strongly with MRK-16 ( Figure 6A and 6B). SBC-3/ADM and H69/VP cells also exhibited P-gp (data not shown).
Binding activity of NK109 with P-gp P-gp is a plasma membrane protein that confers MDR by actively transporting the cytotoxic drugs out of the cells. Therefore, we exanmined the affinity of NK109 for P-gp. Azidopine is a photoaffinity analogue of the dihydropyridine class of calcium channel blockers that specifically labels P-gp (Yang et al, 1988) . Verapamil, a calcium channel blocker, inhibited this labelling, as shown in Figure 7 . Doxorubicin also inhibited photolabelling of P-gp by L3H] azidopine. This result suggests that both verapamil and doxorubicin are substrates for active transport in plasma membrane vesicles prepared from multidrug-resistant K562 cells. In contrast, NK109 does not block photolabelling when present at up to a 100-fold molar excess (Figure 7) , suggesting that NK109 is not a substrate for P-gp and, therefore, that accumulation of NK 109 was not diminished in resistant cells. (1997) Figure 8B . Decatenated forms were not observed for SKOV3/VP even when 0.03 ,ug of nuclear extract was used, indicating that Topo II activity of SKOV3/VP cells was reduced to about one-tenth of that of the parent cells. In contrast, the Topo I activity of SKOV3/VP extracts was not changed compared with the parent cells ( Figure 8A ). These results indicate that the resistance of SKOV3/VP cells to etoposide is due to reduced Topo II activity. Non-cross-resistance of etoposideresistant SKOV3IVP cells to NK109 suggests that the mechanism of action of NK109 differs from that of etoposide.
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In vivo anti-tumour activity of NK109 against drugresistant cells
In order to confirm the in vitro results of non-cross-resistance to NK109 in drug-resistant cells, we checked the transplantability of several human carcinoma cell lines in nude or SCID mice. We found that both PC-14/P and PC-14/CDDP were transplantable in SCID mice, producing high take rates, and thus SCID mice were used in this experiment. Figure 9B shows the mean ILS of cisplatin-treated SCID mice with PC-14/P and PC-14/CDDP cell xenografts. The cisplatin treatment suppressed tumour growth only in the PC-14/P cell line and not in the resistant subline PC-14/CDDP. Therefore, the ILSs for cisplatin (4 mg kg-') for PC-14/P and PC-14/CDDP cells were 44% and 2% respectively. In contrast, the ILSs for NK109 at 100, 125, and 150 mg kg-' for PC-14/P cells were 8%, 26% and 33% respectively. The ILSs for PC-14/CDDP cells were 18%, 25% and 27% respectively as shown in Figure 9A . These data indicate that cisplatin-resistant cells are not cross-resistant to NK109 in vivo, as well as in vitro.
DISCUSSION
Fagaridine isolated from the root bark of Fagara xanthoxyloides was reported to inhibit the growth of certain human leukaemias and several murine tumour cells, and 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium was determined as its chemical structure, which is similar to that of NK109 (Torto and Mensah, 1973; Hanaoka et al, 1985) . However, Kessar et al (1988) indicated an incorrect structure for fagaridine and revised a different placement (at the C-8 position on ring A of benzo[c]phenanthridine) of the hydroxy group. Therefore, the NK109 tested in this study is a different positional isomer from fagaridine and a novel anti-tumour agent.
Its cytotoxic mechanism was confirmed to be due to Topo II inhibition. The topoisomerases are nuclear enzymes that catalyse the concerted breaking and rejoining of DNA strands, thereby controlling the topological states of DNA during many DNA metabolic processes, including replication, recombination, transcription and chromosome segregation at mitosis (Wang, 1985) . They are considered to be important therapeutic targets in cancer chemotherapy. In addition, recent studies have shown that several chemotherapeutic drugs, such as topoisomerase inhibitors, trigger apoptosis (Kaufmann, 1989) . We have also demonstrated that NK109 induces single-and double-strand DNA breaks and DNA fragmentation, which is a marker for apoptosis, in a human smallcell lung cancer cell line. Furthermore, we showed that protein and RNA syntheses were not required for apoptosis induced by NK109 (Fukuda et al, 1996) .
In this study, we determined the efficacy of NK109 against an etoposide-resistant ovarian carcinoma cell line, SKOV3/VP, which has reduced Topo II activity as one of the resistance mechanisms. The resistant cells exhibited marked sensitivity to NK109 compared with their parent cells, suggesting that the cytotoxic mechanism of NK109 differs from that of etoposide. This was supported by the observation that NK109 induces more DNA strand breaks, especially DNA double-strand breaks, than the same concentration of etoposide (Fukuda et al, 1996 Dose (mg kgF1) Dose (mg kg71) Figure 9 Increase in lifespan (ILS) of SCID mice with PC-14/P (0) and PC-14/CDDP (0) cell xenografts, treated by injection (i.p.) of NK109 at doses of 100, 125 and 150 mg kg-' (A) and cisplatin at a dose of 4 mg kg-' (B) as a reference drug on days 0, 4 and 8. ILS was calculated as described in Materials and methods (1993) reported that fagaronine and nitidine being similar to NK109 are characterized as inhibitors of Topo I function.
Therefore, we are studying the ability of NK109 to induce singlestrand DNA breaks or act as a Topo I poison.
The development of multiple resistance to anti-tumour agents by human tumour cells is recognized as one of the major obstacles to successful cancer chemotherapy. MDR is frequently characterized by enhanced drug efflux because of a membrane glycoprotein (P-gp; Mr 170 000) encoded by the MDRJ gene in human cancer cells (Fojo et al, 1985) . The kinetics of drug uptake, accumulation and efflux also suggests that multidrug-resistant cells remove these cytotoxic drugs from the cell by active transport across the plasma (Skovsgaard, 1978) . Overexpression of P-gp is widely observed in various multidrug-resistant cell lines (Dano, 1973) . Further, multidrug-resistant cells selected for resistance to one drug become simultaneously resistant to many other drugs that are structurally and functionally unrelated to the selected drug (Gottesman and Pastan, 1988) . For instance, human KB carcinoma cells selected for resistance to colchicine are also resistant to vinblastine, vincristine, actinomycin D, daunomycin and doxorubicin, but they are not resistant to methotrexate, cytosine arabinoside and dexamethasone (Fojo et al, 1985) .
Some calcium channel blockers, such as verapamil, diltiazem, and dihydropyridine analogues, are reported to reverse the MDR phenotype (Safa et al, 1987; Akiyama et al, 1988) . However, no agent that reverses multidrug resistance can be clinically used in full doses to reverse resistance. Thus, the development of NK109 as a novel anti-tumour drug that is not a substrate for calcium channel blockers of P-gp will be potentially valuable. Moreover, the efficacy of NK109 is not susceptible to several molecular alterations associated with drug resistance. The clinical study of this compound is now in progress in Japan. The drug is clearly very active against resistant solid tumour cell lines, but its clinical toxicity needs elucidation before human clinical efficacy trials.
